Leal, formerly known as Trialjectory, has established a predictive patient platform that offers to 1) help cancer patients navigate their treatment journey at all stages of the disease, 2) educate patients and their oncologists about all of their treatment options in a timely manner to remove barriers to care in advance and 3) enable the pharmaceutical industry to identify potential patients that could match to their trials in the future.
“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.
